• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

    7/31/24 9:15:00 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTGX alert in real time by email

    Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space

    NEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery, pre-clinical and translational research and development leadership to maximize the impact of the Protagonist platform in areas where peptides have the ability to be best-in-class therapeutics.

    "We are very pleased to welcome Dr. Yeilding to Protagonist as our full-time Chief Scientific Advisor," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist. "With extensive experience in research, development, and commercialization of novel therapeutics in the I&I space, Newman will be a great addition to the Protagonist R&D team as we expand our pipeline over the short- and long-term with drug candidates with blockbuster potential, including the oral peptide IL-17 antagonist program."

    "I am delighted to be joining the Protagonist team," said Dr. Yeilding. "Peptide therapeutics have the ability to be significantly more effective than small molecule or antibody-based drugs for many serious and life-threatening diseases. I look forward to working with the Protagonist team to maximize the impact of the company's peptide technology platform and continue bringing meaningful therapeutic innovations out of the lab and into clinical practice and patient care."

    Dr. Yeilding joins Protagonist following his 17-year career at Janssen, where he held a number of senior roles including Head of Immunology Development and R&D, Vice President of Immunology Dermatology, GI Development Senior Director, Vice President Immunology, and STELARA and Early Development Compound Development Team Leader. During his time at Janssen, he provided scientific and management leadership of immunology development initiatives in clinical departments including Rheumatology, Gastroenterology, Dermatology, and Pediatric Development. He led an R&D organization of approximately 250 members in close collaboration with the Immunology Global Strategic Commercial Organization to accelerate development, commercialization, and market access of innovative first-in-class or best-in-class compounds for the global Immunology market. Prior to Janssen, he was the Associate Director of Medical Affairs at Centocor and served as Chief of Hematology-Oncology at the Philadelphia Veterans Administration Medical Center, after spending four years as a research track faculty with research focused on tumor angiogenesis. Dr. Yeilding earned his M.D. from the University of Alabama, Birmingham, and a B.S. from Davidson University in North Carolina.

    About Protagonist
    Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and Johnson & Johnson (JNJ) scientists jointly discovered PN-235 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in the New England Journal of Medicine in February 2024. The 1-year open-label extension (OLE) component of Phase 2 REVIVE is ongoing, followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.

    More information on Protagonist and its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.

    Cautionary Note on Forward-Looking Statements
    This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of JNJ-2113 and rusfertide, the timing of JNJ-2113 and rusfertide clinical trials, and timing of developments in our discovery programs. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

    Investor Relations Contact
    Corey Davis, Ph.D.
    LifeSci Advisors
    [email protected]
    +1 212 915 2577

    Media Relations Contact
    Virginia Amann
    ENTENTE Network of Companies
    [email protected]
    +1 833 500 0061

    SOURCE: Protagonist Therapeutics, Inc.



    View the original press release on accesswire.com

    Get the next $PTGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTGX

    DatePrice TargetRatingAnalyst
    12/6/2024$47.00Neutral
    Goldman
    12/6/2024$62.00Outperform
    BMO Capital Markets
    11/5/2024$58.00Outperform
    Wedbush
    9/24/2024$65.00Buy
    TD Cowen
    9/9/2024$60.00Buy
    Truist
    10/30/2023$32.00Overweight
    CapitalOne
    5/25/2023$30.00 → $40.00Buy
    Jefferies
    8/25/2022$21.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $PTGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/14/24 4:27:37 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/12/24 4:51:49 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

      SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

      11/4/24 1:22:14 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

      Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

      6/1/25 8:00:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Reports Granting of Inducement Awards

      NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeilding served in a consultant role as the Company's Chief Scientific Advisor from August 1, 2024 through January 1, 2025. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.Dr. Yeilding received options to purchase 38,520 sh

      1/6/25 4:05:00 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.

      SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)

      5/13/25 12:10:05 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Protagonist Therapeutics Inc.

      10-Q - Protagonist Therapeutics, Inc (0001377121) (Filer)

      5/6/25 5:04:48 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)

      5/6/25 4:27:37 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Protagonist Therapeutics with a new price target

      Goldman initiated coverage of Protagonist Therapeutics with a rating of Neutral and set a new price target of $47.00

      12/6/24 8:23:16 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets initiated coverage on Protagonist Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $62.00

      12/6/24 8:11:17 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Protagonist Therapeutics with a new price target

      Wedbush initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $58.00

      11/5/24 6:25:30 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Selick Harold E exercised 10,725 shares at a strike of $1.16, increasing direct ownership by 32% to 43,851 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      4/30/25 4:45:59 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Ali Asif sold $80,776 worth of shares (1,756 units at $46.00), decreasing direct ownership by 3% to 61,065 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      4/23/25 4:30:15 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Waddill William D. sold $217,000 worth of shares (4,000 units at $54.25), decreasing direct ownership by 23% to 13,130 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      3/19/25 4:01:12 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Financials

    Live finance-specific insights

    See more
    • Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

      Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

      6/1/25 8:00:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

      Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL

      11/21/24 4:05:00 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

      Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery,

      7/31/24 9:15:00 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Set to Join S&P SmallCap 600

      NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a

      6/27/24 5:44:00 PM ET
      $PTGX
      $SPGI
      $WIRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)